# Christopher Fuglesang > Christopher Fuglesang is a Series B investor at Eidogen-Sertanty backing Biotechnology. See 9 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Eidogen-Sertanty](https://shizune.co/investors/profile/eidogen-sertanty) - Total investments: 9 - Last investment: Nov 2021 - Lead investor: 33% - Last updated: Aug 2026 Christopher Fuglesang is a Series B investor at Eidogen-Sertanty focused on Biotechnology and Health Care. Christopher Fuglesang, Ph.D., J.D., joined Tavistock Life Sciences in 2005 and is responsible for co-managing the group's public market activities, including identifying investment opportunities involving new drugs and medical devices, clinical and regulatory strategies, capital structuring, partnering, merger and acquisition strategies aswell as intellectual property strategies.In this role, Dr. Fuglesang has handled and supervised a variety of public business transactions, including public offerings, mergers and acquisitions, joint ventures and other strategic collaborations and commercial transactions in the healthcare space. Dr. Fuglesang brings with him years of experience in building and developing life science companies, previously founding as well as holding executive management positions at various biotech companies. His responsibilities in these positions included intellectual property management, licensing and corporate development.Currently, Dr. Fuglesang is a member of the board of directors at Ambrx, Kalypsys. And Eidogen-Sertany.Dr. Fuglesang holds a doctorate in chemical physics from the University of California, Los Angeles, a juris doctor from the Boston University School of Law and bachelor's degrees in both chemistry and physics from the University of California, Los Angeles. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 4 | 44% | | Health Care | 3 | 33% | | Therapeutics | 3 | 33% | | Medical | 2 | 22% | | Life Science | 2 | 22% | 7 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 4 | 44% | | Series A | 2 | 22% | | Series C | 2 | 22% | | Series D | 1 | 11% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Shoreline Biosciences | Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cellsto improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA. | $140M | Series B | Nov 02, 2021 | | | Shoreline Biosciences | Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cellsto improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA. | $43M | Series A | Feb 07, 2021 | | | Pandion Therapeutics | Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants.Pandion’s approach has the potential to more effectively induce and sustainresponse and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety. | $80M | Series B | Apr 01, 2020 | | | Ambrx | Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeuticpeptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. | $10M | Series D | Apr 01, 2009 | | | Kalypsys | Kalypsys provides pathway-based drug discovery and development services. The company implements discovery programs across a broad number of therapeutic areas using its automated and integrated suite of discovery technologies in biology, chemistry and informatics. | $100M | Series C | Nov 29, 2006 | | | Ambrx | Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeuticpeptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. | $52M | Series C | Jul 05, 2006 | | | Ambrx | Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeuticpeptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. | $5M | Series B | Jan 25, 2006 | | | Ambrx | Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeuticpeptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. | $23.4M | Series A | Mar 21, 2005 | | | Kalypsys | Kalypsys provides pathway-based drug discovery and development services. The company implements discovery programs across a broad number of therapeutic areas using its automated and integrated suite of discovery technologies in biology, chemistry and informatics. | $29M | Series B | Aug 05, 2004 | | 9 of 9 investments shown. ## Co-investors - [Tavistock Life Sciences](https://shizune.co/investors/profile/tavistock-group) — VC Fund, 6 deals together - [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 2 deals together - [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners) — VC Fund, 2 deals together - [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 2 deals together - [Commodore Capital](https://shizune.co/investors/profile/commodore-capital) — VC Fund, 2 deals together - [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 2 deals together ## About Eidogen-Sertanty VC Fund 1 contacts available at Eidogen-Sertanty. | Name | Title | Profile | | --- | --- | --- | | Christopher Fuglesang | Board of Directors | https://shizune.co/investors/profile/christopher-fuglesang | ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does Christopher Fuglesang invest in? Christopher Fuglesang invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Christopher Fuglesang last invest? The most recent investment recorded for Christopher Fuglesang closed in Nov 2021. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co